A novel method for potentiation of chemotherapy in soft tissue sarcomas with BromAc.
Ontology highlight
ABSTRACT: Single-agent doxorubicin currently forms part of standard care for patients with sarcomas. However, efficacy is limited by the presence of dose-dependent cardiotoxicity and toxicity to renal, hepatic, and neurological systems. Therefore, there is a pressing need for novel drug regimens which can provide increased efficacy and safety. BromAc is a novel drug combination developed as a mucolytic agent which has demonstrated anticancer activity both in vitro and in vivo in several cancers. Here, we investigated the efficacy of BromAc in combination with doxorubicin for four subtypes of sarcoma. Cell proliferation, alongside western blot for a variety of cell cycle, apoptosis, and autophagy biomarkers assays was performed following treatment of cell lines in vitro at various concentrations of B
SUBMITTER: Dong L
PROVIDER: S-EPMC9185037 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature
ACCESS DATA